Fig. 2From: PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancersDNA repair processes with the aids of poly (ADP-ribose) polymerase. (Notes: XRCC1, X-ray cross complementing protein 1; ATM, ataxia telangiectasia-mutated kinase; MRE11, mitotic recombination 11. Others include: - Nijmegen breakage syndrome 1 (Nbs1), DNA ligase III, and DNA polymerase β)Back to article page